Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
| Revenue (TTM) | $989.36M |
| Gross Profit (TTM) | $732.42M |
| EBITDA | $244.70M |
| Operating Margin | 20.20% |
| Return on Equity | 18.70% |
| Return on Assets | 10.20% |
| Revenue/Share (TTM) | $17.07 |
| Book Value | $18.26 |
| Price-to-Book | 1.78 |
| Price-to-Sales (TTM) | 1.97 |
| EV/Revenue | 1.298 |
| EV/EBITDA | 4.74 |
| Quarterly Earnings Growth (YoY) | -6.90% |
| Quarterly Revenue Growth (YoY) | 12.30% |
| Shares Outstanding | $58.72M |
| Float | $52.53M |
| % Insiders | 1.21% |
| % Institutions | 102.48% |
Volatility is currently expanding
Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.
Harmony Biosciences NASDAQ: HRMY reported third-quarter net revenue of $269 million, up from $239 million a year earlier, as demand for its narcolepsy treatment WAKIX continued to grow. The company reiterated its full-year WAKIX net revenue guidance of $1 billion to $1.04 billion and said it expects to exceed $1 billion in annual WAKIX revenue for the first time.
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.87 per share a year ago.
WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Technical indicators have turned bullish for the Barron's Investor Circle stock picks.
Harmony Biosciences is rated Buy with a 12-month price target of $43, reflecting strong cash generation and WAKIX growth. HRMY's valuation is supported by WAKIX's robust performance, cash reserves, and limited downside if patents hold through 2030. Key risks include the pending AET patent litigation and management turnover, with significant near-term binary events ahead.
PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on November 4, 2026, at 8:30 a.m. ET to discuss the results.
Harmony Biosciences gains 27.6% in six months as Wakix sales surge and pipeline advances, with new formulations and clinical milestones offering further growth opportunities.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HRMY and any ticker you trade — then tracks every position and per-strategy win rate.
